Wahlstrom Mats
- SEC CIK
- 0001459154
In the past year, 1 open-market purchase filing worth $151.8K and no sales.
Current role at each company
- CHRS Coherus Oncology, Inc.Directoras of Jun 9, 2026
- TLSI TriSalus Life Sciences, Inc.Directoras of May 18, 2026
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- $151.8K
- 1 filing
- Sold
- –
- 0 filings
- Net
- +$151.8K
- Bought minus sold
- Companies
- 1
- With open-market trades
Trades
Every Form 4 that lists Wahlstrom Mats as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
TLSI TriSalus Life Sciences, Inc.
Director3 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| May 18, 2026 (view filing) | May 15 | 3 days | Wahlstrom MatsDirector | PPurchase | +60.0K | $2.53 | +$151.8K | +68.5%147.6K after | |
| Nov 25, 2024 (view filing) | Nov 22 | 3 days | Wahlstrom MatsDirector, 10% Owner | PPurchase | +5.00K | $4.55 | +$22.8K | +46.6%15.7K after | |
| Nov 22, 2024 (view filing) | Nov 20-21 | 2 days | Wahlstrom MatsDirector, 10% Owner | PPurchase | +10.7K | $4.39 | +$47.1K | New position10.7K after | 2 lots |
CHRS Coherus Oncology, Inc.
Director1 trade
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| May 28, 2025 (view filing) | May 23 | 5 days | Wahlstrom MatsDirector | SSale | −100.0K | $0.74 | −$74.0K | −100.0%0 after |